Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.
Mitochondrial:nuclear DNA (mtDNA:nDNA) ratios in blood cells were investigated in relation to selected human immunodeficiency virus antiretroviral drug regimens. Patients (n = 214) continually received a regimen consisting of either (1) saquinavir (SAQ) + ritonavir (RTV) + either nevirapine (NVP) or lamivudine (3TC) (n=32) or (2) SAQ+RTV (+/- either NVP or 3TC) + either stavudine (d4T) (n=127), didanosine (ddI) (n=19), d4T+ddI (n=21), or zidovudine (ZDV) (n=15), for >/=4 months. NVP- or 3TC-only regimens were associated with median mtDNA:nDNA ratios that were significantly higher than those for ddI- and d4T+ddI-containing regimens (P<.01) but that were not significantly higher than those for d4T- or ZDV-containing regimens. Patients received thymidine analogue- and/or ddI-containing regimens for a shorter time (median, 14 vs. 24 months; P<.01). Because of survivor-bias effect, these results may represent a conservative estimate of these nucleosides' effect on mtDNA.
Côté
Hélène C F
HC
B.C. Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Department of Medicine, University of British Columbia, Vancouver, Canada.
Yip
Benita
B
Asselin
Jérôme J
JJ
Chan
Jennifer W
JW
Hogg
Robert S
RS
Harrigan
P Richard
PR
O'Shaughnessy
Michael V
MV
Montaner
Julio S G
JS
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D004247:DNA / Q000187:drug effects*; D004272:DNA, Mitochondrial / Q000187:drug effects*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D008297:Male
D019380:Anti-HIV Agents; D004272:DNA, Mitochondrial; D004247:DNA